Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercell's Pipeline Setbacks Force Strategic Rethink, Highlight Downside of Option-Based Deals

Jun 20 2011

• By John Davis

Related Content

Why Wyeth's Talking Up Vaccines

Jan 01 2008

Novartis Vaccines Portfolio Gets A Boost With Access To Intercell Technology

Jul 02 2007

Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell

Sep 17 2010

Novartis’ New Vaccine Division Takes On Evolving Market

Jul 31 2006

Intercell Reaches Commercial Stage In US: Japanese Encephalitis Vaccine Gets FDA Okay

Apr 01 2009

Glaxo Buys A Stake In Intercell And Gains Access To Patch Vaccine Techology

Dec 11 2009

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window